Articles
Page 20 of 23
-
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P80
-
Activation profile of cGMP-dependent protein kinase Iα
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P79 -
Genes involved in pulmonary hypertension of mice with endothelial-specific ablation of guanylyl cyclase A
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P77 -
Analysis of cGMP signalling with transgenic mice expressing FRET-based cGMP sensors
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P76 -
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P75 -
Endothelial GC-A can be a therapeutic target for metabolic syndrome
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P73 -
Differential regulation of platelet inhibition by cGMP- and cAMP-dependent protein kinases
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P69 -
Cardiac cGMP/cGMP-dependent protein kinase I signalling requires cysteine-rich LIM-only protein 4 (CRP4) to oppose angiotensin II induced hypertrophy and fibrosis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P68 -
Fishing for elusive cCMP-degrading phosphodiesterases
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P62 -
Potent inhibition of nitroglycerin bioactivation by diphenyleneiodonium (DIP)
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P49 -
Video microscopy as a tool to visualize cGMP effects on contractility and sperm transport in seminiferous tubules and the epididymal duct
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P44 -
Alternative splicing of α1 and β1 sGC genes is altered in aortic disease
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P42 -
Evidence for functional coupling of cGMP/cGKI signalling and TRPC channels in endothelium but not in vascular smooth muscle
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P40 -
Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX ouse model of Duchenne muscular dystrophy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O38 -
A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P38 -
Pseudomonas aeruginosaExoY, a cyclic GMP- and cyclic UMP-generating nucleotidyl cyclase
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O36 -
Increases survival by apo-sGC activation via post-stroke blood brain barrier stabilisation and anti-inflammation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P36 -
Interstitial cells of Cajal plasticity rather than regeneration restores slow-wave activity and enteric neurotransmission upon acute damage
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P34 -
A novel physiological significance of natriuretic peptides in cancer metastasis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O34 -
NO-H2S interactions involve cGMP
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O32 -
Cyclic GMP-mediated intercellular communication in mammalian ovarian follicles
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P31 -
Interstitial cells of Cajal link excitatory and nitrergic inhibitory neurotransmission with slow-wave activity in the intestine
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O30 -
Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P30 -
GUCY2C at the intersection of obesity and colorectal cancer
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O28 -
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P23 -
Chronic beta-adrenergic blockade prevents volume overload-induced re-localization and oxidation of soluble guanylyl cyclase
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O22 -
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P22 -
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P21 -
Structures of human PKG reveal cGMP-selectived activation mechanisms
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O16 -
Soluble guanylate cyclase crystal clear: 1stcrystal structure of the wild-type human heterodimeric sGC catalytic domains and implications for activity
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O14 -
Receptor guanylyl cyclase-G is a novel thermosensor in Grueneberg ganglion neurons involved in coolness-induced ultrasonic distress calls in mice
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P14 -
Identification and quantitation of 2´,3´-cGMP in murine tissues
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P12 -
G-protein signaling modulator 1 is a modifier of sGC-dependent vascular response
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P11 -
NO-cGMP signalling and cancer therapy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P9 -
Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P7 -
Effects of omeprazole and AlOH/MgOH on riociguat absorption
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P6 -
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P5 -
Effect of nitrite treatment on endothelial nitric oxide synthase in human left ventricle biopsy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P3 -
Hydroxyurea reduces leukocyte interactions with the vessel wall in a haemolytic mouse model via a possible NO/cGMP-mediated effect
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P2 -
Increased nitrosative/oxidative stress lowers myocardial protein kinase G activity in heart failure with preserved ejection fraction
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O2 -
Memory loss during lenalidomide treatment: a report on two cases
There are many reports of cognitive dysfunction in patients receiving chemotherapy or targeted therapies. Many antineoplastic agents may be involved in the condition also known as “chemo brain” or “chemo fog”.
Citation: BMC Pharmacology and Toxicology 2013 14:41 -
Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents treated for systemic-onset juvenile idiopathic arthritis (SJIA) and autoinflammatory syndromes.
Citation: BMC Pharmacology and Toxicology 2013 14:40 -
The association between prescription change frequency, chronic disease score and hospital admissions: a case control study
The aim of this study was to assess the association between prescription changes frequency (PCF) and hospital admissions and to compare the PCF to the Chronic Disease Score (CDS). The CDS measures comorbidity ...
Citation: BMC Pharmacology and Toxicology 2013 14:39 -
Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance
Olanzapine use has been reported during pregnancy and breastfeeding, but there are no controlled clinical trials assessing the safety of olanzapine exposure to infants and fetuses. The purpose of this report w...
Citation: BMC Pharmacology and Toxicology 2013 14:38 -
Polycomblike protein PHF1b: a transcriptional sensor for GABA receptor activity
The γ-aminobutyric acid (GABA) type A receptor (GABAAR) contains the recognition sites for a variety of agents used in the treatment of brain disorders, including anxiety and epilepsy. A better understanding of h...
Citation: BMC Pharmacology and Toxicology 2013 14:37 -
Coumestrol from the national cancer Institute’s natural product library is a novel inhibitor of protein kinase CK2
Casein kinase 2 (CK2) is involved in various cellular events such as proliferation, apoptosis, and the cell cycle. CK2 overexpression is associated with multiple human cancers and may therefore be a promising ...
Citation: BMC Pharmacology and Toxicology 2013 14:36 -
Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine
Amphetamine and amphetamine derivatives are suggested to induce an immunosuppressive effect. However, knowledge of how amphetamines modulate intracellular signaling pathways in cells of the immune system is li...
Citation: BMC Pharmacology and Toxicology 2013 14:35 -
Quantitation of small intestinal permeability during normal human drug absorption
Understanding the quantitative relationship between a drug’s physical chemical properties and its rate of intestinal absorption (QSAR) is critical for selecting candidate drugs. Because of limited experimental...
Citation: BMC Pharmacology and Toxicology 2013 14:34 -
Effects of packaging and storage conditions on the quality of amoxicillin-clavulanic acid – an analysis of Cambodian samples
The use of substandard and degraded medicines is a major public health problem in developing countries such as Cambodia. A collaborative study was conducted to evaluate the quality of amoxicillin–clavulanic ac...
Citation: BMC Pharmacology and Toxicology 2013 14:33 -
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
Dormant cells are characterised by low RNA synthesis. In contrast, cancer cells can be addicted to high RNA synthesis, including synthesis of survival molecules. We hypothesised that dormant cancer cells, alre...
Citation: BMC Pharmacology and Toxicology 2013 14:32
Annual Journal Metrics
-
2022 Citation Impact
2.9 - 2-year Impact Factor
2.9 - 5-year Impact Factor
0.932 - SNIP (Source Normalized Impact per Paper)
0.603 - SJR (SCImago Journal Rank)2022 Speed
22 days submission to first editorial decision for all manuscripts (Median)
198 days submission to accept (Median)2022 Usage
642,939 downloads
1,154 Altmetric mentions
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication